NCT02655549View on ClinicalTrials.gov

A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Anthrax
Interventions
BIOLOGICAL

Px563L, RPA563, or placebo

Two intramuscular injections

Trial Locations (1)

66211

Quintiles Phase One Services, Overland Park

Sponsors

Lead Sponsor

Pfenex, Inc
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Pfenex, Inc

INDUSTRY